Home › Funds › Context Capital Management, LLC › BBIO

Context Capital Management, LLC position in BBIO

BRIDGEBIO PHARMA INC · Health Care

Context Capital Management, LLC reported holding 56,666,000 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q2 2026 13F filing — a position valued at US$62.9M, representing 1.83% of its reported portfolio and ranking #18 among its reported holdings. Context Capital Management, LLC has disclosed BBIO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)56.67M sh
Reported value held$62.92M
Portfolio Weight1.83%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Context Capital Management, LLC's BBIO position evolved

Context Capital Management, LLC first disclosed a stake in BBIO in Q3 2023 at 6,110 shares (US$5.9M). The position peaked in Q1 2025 at 70,404 shares, worth US$63.47B. Across 12 filings, Context Capital Management, LLC increased the stake 8 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 56,666,000 shares valued at US$62.9M — a reduction of -14,588,000 shares quarter over quarter.. Notable position changes include a 1700% increase in Q4 2023 (shares fell 23% over the following quarter), a 43845% increase in Q2 2024 (shares were roughly flat over the following quarter), a 81403% increase in Q4 2025 (shares fell 3% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 6.11K $5.86M New
Q4 2023 110.00K $133.16M Add
Q1 2024 110 $118.22M Reduce
Q2 2024 48.34K $38.52B Add
Q3 2024 61.34K $51.52B Add
Q4 2024 68.90K $59.12B Add
Q1 2025 70.40K $63.47B Add
Q2 2025 72.70K $68.05M Add
Q3 2025 97.85K $96.70M Add
Q4 2025 79.75M $89.82M Add
Q1 2026 71.25M $79.94M Reduce
Q2 2026 56.67M $62.92M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBIO and 13F data

BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 47 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), Farallon Capital Management (US$800.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBIO

All BBIO fund holders →

FAQ

How long has Context Capital Management, LLC held BBIO?

Context Capital Management, LLC has disclosed BBIO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Context Capital Management, LLC's current position in BBIO?

As of Q2 2026, Context Capital Management, LLC holds 56.67M shares of BBIO (BRIDGEBIO PHARMA INC), valued at $62.92M, representing 1.83% of its reported portfolio and ranking #18.

Has Context Capital Management, LLC been buying or selling BBIO?

In the latest 13F filing (Q2 2026), Context Capital Management, LLC reduced its position in BBIO. The position peaked in Q1 2025 at 70.40K shares.

Which other funds hold BBIO?

Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, Farallon Capital Management, among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.